The Spondyloarthritis (Spondyloarthropathy) drugs in development market research report provides comprehensive information on the therapeutics under development for Spondyloarthritis (Spondyloarthropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Spondyloarthritis (Spondyloarthropathy). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Spondyloarthritis (Spondyloarthropathy) and features dormant and discontinued products.

GlobalData tracks five drugs in development for Spondyloarthritis (Spondyloarthropathy) by five companies/universities/institutes. The top development phase for Spondyloarthritis (Spondyloarthropathy) is preclinical with two drugs in that stage. The Spondyloarthritis (Spondyloarthropathy) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Spondyloarthritis (Spondyloarthropathy) pipeline products market are: Boehringer Ingelheim International, AbbVie and Alma Bio Therapeutics.

The key targets in the Spondyloarthritis (Spondyloarthropathy) pipeline products market include Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG), and Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

The key mechanisms of action in the Spondyloarthritis (Spondyloarthropathy) pipeline product include Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Antagonist with one drug in Discovery. The Spondyloarthritis (Spondyloarthropathy) pipeline products include two routes of administration with the top ROA being Intramuscular and four key molecule types in the Spondyloarthritis (Spondyloarthropathy) pipeline products market including Small Molecule, and Biologic.

Spondyloarthritis (Spondyloarthropathy) overview

Spondyloarthritis is an inflammatory arthritis characterized by inflammation of spine (spondylitis) and joints (arthritis). Lower back pain is its main symptom. Types of spondyloarthritis include ankylosing spondylitis, axial spondyloarthritis, enteropathic spondyloarthritis, peripheral spondyloarthritis, psoriatic arthritis, and reactive arthritis. It is believed that spondyloarthritis may be developed through the interaction of genetic and environmental factors. Symptoms include back pain and stiffness, fatigue, painful swelling of the joints, and episodes of eye inflammation. It can be diagnosed with the help of blood tests identifying HLA-B27 (a gene variant that controls immune responses) and through imaging studies. Treatment options includes NSAIDS, DMARDS TNF inhibitors, IL-17A inhibitors, and other biologics, which are also used to treat peripheral spondyloarthritis.

For a complete picture of Spondyloarthritis (Spondyloarthropathy)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.